<DOC>
	<DOCNO>NCT01938235</DOCNO>
	<brief_summary>This study aim assess effect exenatide myocardial injury patient undergoing emergent percutaneous coronary intervention ( PCI ) ST segment elevation myocardial infarction heart attack ( STEMI ) .</brief_summary>
	<brief_title>Exenatide Myocardial Protection During Reperfusion Study</brief_title>
	<detailed_description>This Phase II randomize , double-blind , placebo-controlled study patient STEMI . Those agree participate immediately randomize one two group : 24-h infusion exenatide ; 24 h infusion placebo . We assess ability exenatide reduce ischemic injury . This study serve safety evaluation study well pilot large multicentre trial power clinical outcome .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Admission primary PCI STEMI , enrollment within 12 hour onset symptom . STEMI define typical ECG change ( ST segment elevation ≥1mm 2 limb lead , ≥2mm 2 precordial lead , new onset LBBB ) associate acute chest pain elevation cardiac enzyme . Antegrade TIMI 0 1 prior PCI infarctrelated artery Age ≥18 year Symptomatic hypoglycemia ( serum glucose &lt; 3.3 µmol/L ; 60 mg/dl ) Diabetes mellitus require insulin therapy Diabetic ketoacidosis Coronary anatomy warrant emergent coronary artery bypass graft surgery Mechanical complication STEMI ( ventricular septal rupture , free wall rupture , acute severe mitral regurgitation ) Need hemodialysis Malignancy , HIV , central nervous system disorder Cardiopulmonary resuscitation &gt; 15 min compromise level consciousness . Cardiogenic shock Current participation research study involve investigational drug device Inability give inform consent Inability safely undergo cMRI ( presence cardiac pacemaker , implanted cardiac defibrillator , aneurysm clip , carotid artery vascular clamp , neurostimulator , implant drug infusion device , bone growth/fusion stimulator , cochlear , otologic , ear implant , severe claustrophobia ) Women childbearing potential know pregnant lactate positive pregnancy test admission History pancreatitis Known end stage renal failure know eGFR &lt; 30 mL/min Currently take exenatide ( Byetta , Bydureon ) , liraglutide ( Victoza ) , GLP1 agonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Reperfusion injury</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Magnetic resonance imaging</keyword>
</DOC>